查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771503

全球多发性硬化症治疗药物市场：市场规模、份额和趋势分析（按药物类别、给药途径、分销管道和地区）、按细分市场预测（2025-2030 年）

Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressants, Immunostimulants), By Route Of Administration (Oral, Injectable), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

多发性硬化症药物市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球多发性硬化症药物市场规模预计到2030年将达到386.2亿美元，2025年至2030年的复合年增长率为5.93%。

新兴市场巨大的未满足临床需求是多发性硬化症药物市场最具影响力的驱动因素之一。全球许多组织积极参与传播进行性多发性硬化症及其相关疾病的认知。其中，值得关注的例子包括美国多发性硬化症协会 (NMSS)、加拿大多发性硬化症国际联合会、欧洲多发性硬化症平台 (EMSP) 和多发性硬化症协会 (MSC)。

预计报销计画也将增加多发性硬化症药物的用量。例如，2014年6月，加拿大百健艾迪公司宣布，其多发性硬化症治疗药物TECFIDERA现已在英国哥伦比亚省透过BC省药物补贴计画（BC PharmaCare）获得报销。

预计剂量最小、成本低廉的新型治疗方法的推出将进一步推动市场增长 - 例如，赛诺菲的 Lemtrada 每年只需服用三到五次，而 Copaxone 则需要每天服用。

多发性硬化症药物市场：概述

  • 根据药物类别，免疫抑制剂将在 2024 年占据市场主导地位，收入为 60.50%。强大的药物管道和未来六年内预期的商业化是预计推动市场成长的一些因素。
  • 根据给药途径，口服製剂在预测期内预计将以最快的复合年增长率成长。
  • 2024年，注射剂市场占有最大份额，为52.50%。
  • 到 2024 年，北美将占据全球市场的主导地位，占有 38.28% 的份额。多发性硬化症盛行率的上升、新药的推出以及美国Tysabri和 Overgeo 等药品价格高昂是推动其主导的一些因素。

目录

第一章 分析方法与范围

第二章执行摘要

3. 多发性硬化症药物市场：驱动因素、趋势与范围

  • 市场概况/相关展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 多发性硬化症药物市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章 多发性硬化症药物市场：按药物类别的估计和趋势分析

  • 细分仪表板
  • 多发性硬化症药物市场：以药物类别进行趋势分析（2024 年和 2030 年）
  • 免疫抑制剂
  • 免疫刺激剂

第五章 多发性硬化症药物市场：依给药途径的估计与趋势分析

  • 细分仪表板
  • 多发性硬化症药物市场：按给药途径分類的趋势分析（2024 年和 2030 年）
  • 口服
  • 注射
  • 其他的

第六章 多发性硬化症药物市场：按分销管道进行的估计和趋势分析

  • 细分仪表板
  • 多发性硬化症药物市场：按分销管道分類的趋势分析（2024 年和 2030 年）
  • 医院药房
  • 零售药局
  • 电子商务

第七章多发性硬化症药物市场：按地区估计和趋势分析

  • 多发性硬化症药物市场占有率（2024 年及 2030 年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Biogen
    • Bayer AG
    • Sanofi
    • F. Hoffman-La Roche Ltd
    • Johnson &Johnson Services, Inc.
    • Merck &Co., Inc.
    • Takeda Pharmaceuticals Company Limited.
    • Horizon Therapeutics plc
Product Code: 978-1-68038-833-6

Multiple Sclerosis Therapeutic Market Growth & Trends:

The global multiple sclerosis therapeutic market size is estimated to reach USD 38.62 billion by 2030, registering a CAGR of 5.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

Multiple Sclerosis Therapeutic Market Report Highlights:

  • Based on drug class, the immunosuppressant segment dominated the market with the largest revenue share of 60.50% in 2024. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth.
  • Based on route of administration, the oral segment is expected to grow at the fastest CAGR rate over the forecast period, propelled by increasing patient preference for convenient, home-based treatment options.
  • In 2024, the injectable market held the largest share of 52.50% in 2024, owing to high prescription rates & price.
  • North America dominated the global market with a share of 38.28% in 2024. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Multiple Sclerosis Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Multiple Sclerosis Therapeutic Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
    • 3.4.3. Pipeline Analysis, By Phase

Chapter 4. Multiple Sclerosis Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Multiple Sclerosis Therapeutic Market: Drug Class Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Immunosuppressants
    • 4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunostimulants
    • 4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Multiple Sclerosis Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Multiple Sclerosis Therapeutic Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Oral
    • 5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Multiple Sclerosis Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Multiple Sclerosis Therapeutic Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. E-Commerce
    • 6.5.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Multiple Sclerosis Therapeutic Market: Regional Estimates & Trend Analysis

  • 7.1. Multiple Sclerosis Therapeutic Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Teva Pharmaceutical Industries Ltd.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Biogen
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bayer AG
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. F. Hoffman-La Roche Ltd
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Johnson & Johnson Services, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Merck & Co., Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Takeda Pharmaceuticals Company Limited.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Horizon Therapeutics plc
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 4 Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 8 North America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11 U.S Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 14 Canada Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Mexico Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Europe Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 24 UK Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 UK Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Germany Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Germany Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million))
  • Table 28 Germany Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 30 France Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 France Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Italy Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Italy Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Spain Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 Spain Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Denmark Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Denmark Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Sweden Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 Norway Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Norway Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Japan Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 Japan Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 China Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 55 China Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 China Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 58 India Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 India Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 61 South Korea Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 64 Australia Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Australia Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Thailand Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 71 Latin America Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 74 Brazil Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 77 Argentina Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 84 South Africa Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 UAE Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 87 UAE Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 UAE Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Multiple Sclerosis Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Multiple Sclerosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Multiple Sclerosis Therapeutics Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Multiple Sclerosis Therapeutics market: Drug Class outlook and key takeaways
  • Fig. 15 Multiple Sclerosis Therapeutics market: Drug Class movement analysis & market share 2024 & 2030
  • Fig. 16 Immunosuppressants market, 2018 - 2030 (USD Million)
  • Fig. 17 Immunostimulants market, 2018 - 2030 (USD Million)
  • Fig. 18 Multiple Sclerosis Therapeutics market: Route of Administration outlook and key takeaways
  • Fig. 19 Multiple Sclerosis Therapeutics market: Route of Administration movement analysis & market share 2024 & 2030
  • Fig. 20 Oral Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 21 Injectable Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 22 Others Multiple Sclerosis Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 23 Multiple Sclerosis Therapeutics market: Distribution Channel outlook and key takeaways
  • Fig. 24 Multiple Sclerosis Therapeutics market: Distribution Channel movement analysis & market share 2024 & 2030
  • Fig. 25 Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 26 Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 27 E-Commerce, 2018 - 2030 (USD Million)
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Outlook, 2024 & 2030
  • Fig. 30 Regional Market Dashboard
  • Fig. 31 Regional Market Place: Key Takeaways
  • Fig. 32 North America
  • Fig. 33 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Key Country Dynamics
  • Fig. 35 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Canada Key Country Dynamics
  • Fig. 37 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico Key Country Dynamics
  • Fig. 39 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Europe
  • Fig. 41 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 42 UK Key Country Dynamics
  • Fig. 43 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Germany Key Country Dynamics
  • Fig. 45 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 46 France Key Country Dynamics
  • Fig. 47 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Italy Key Country Dynamics
  • Fig. 49 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Spain Key Country Dynamics
  • Fig. 51 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark Key Country Dynamics
  • Fig. 53 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden Key Country Dynamics
  • Fig. 55 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Norway Key Country Dynamics
  • Fig. 57 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific
  • Fig. 59 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Japan Key Country Dynamics
  • Fig. 61 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 62 China Key Country Dynamics
  • Fig. 63 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 64 India Key Country Dynamics
  • Fig. 65 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Australia Key Country Dynamics
  • Fig. 67 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand Key Country Dynamics
  • Fig. 69 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea Key Country Dynamics
  • Fig. 71 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Latin America
  • Fig. 73 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil Key Country Dynamics
  • Fig. 75 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina Key Country Dynamics
  • Fig. 77 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 78 MEA
  • Fig. 79 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 80 South Africa Key Country Dynamics
  • Fig. 81 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Saudi Arabia Key Country Dynamics
  • Fig. 83 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 84 UAE Key Country Dynamics
  • Fig. 85 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait Key Country Dynamics
  • Fig. 87 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Strategy Mapping